Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,616,000 | 6,896,000 | 9,882,000 | 9,799,000 | 6,838,000 |
| Marketable Securities | 351,000 | 383,000 | 288,000 | 450,000 | 310,000 |
| Receivables | 6,925,000 | 6,565,000 | 6,218,000 | 6,487,000 | 6,414,000 |
| Inventories | 6,194,000 | 6,570,000 | 6,173,000 | 5,157,000 | 5,012,000 |
| TOTAL | $23,656,000 | $22,670,000 | $25,224,000 | $24,239,000 | $20,441,000 |
| Non-Current Assets | |||||
| PPE Net | 10,658,000 | 10,154,000 | 9,162,000 | 8,959,000 | 9,029,000 |
| Investments And Advances | 886,000 | 799,000 | 766,000 | 816,000 | 821,000 |
| Intangibles | 29,755,000 | 32,494,000 | 33,253,000 | 35,970,000 | 38,528,000 |
| Other Non-Current Assets | 16,459,000 | 7,097,000 | 6,033,000 | 5,212,000 | 3,729,000 |
| TOTAL | $57,758,000 | $50,544,000 | $49,214,000 | $50,957,000 | $52,107,000 |
| Total Assets | $81,414,000 | $73,214,000 | $74,438,000 | $75,196,000 | $72,548,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,500,000 | 1,080,000 | 2,251,000 | 754,000 | 7,000 |
| Accounts payable and accrued liabilities | 4,195,000 | 4,295,000 | 4,607,000 | 4,408,000 | 3,946,000 |
| Accrued Expenses | 1,701,000 | 1,597,000 | 1,556,000 | 1,625,000 | 1,416,000 |
| TOTAL | $14,157,000 | $13,841,000 | $15,489,000 | $13,105,000 | $11,907,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 12,625,000 | 13,599,000 | 14,522,000 | 17,296,000 | 18,527,000 |
| Other Non-Current Liabilities | 6,731,000 | 6,947,000 | 7,522,000 | 8,771,000 | 9,111,000 |
| TOTAL | $19,356,000 | $20,546,000 | $22,044,000 | $26,067,000 | $27,638,000 |
| Total Liabilities | $33,513,000 | $34,387,000 | $37,533,000 | $39,172,000 | $39,545,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,734,323 | 1,735,184 | 1,737,946 | 1,763,482 | 1,771,529 |
| Common Shares | 25,153,000 | 24,869,000 | 24,709,000 | 24,470,000 | 24,145,000 |
| Retained earnings | 47,261,000 | 37,554,000 | 35,257,000 | 31,528,000 | 27,627,000 |
| Other shareholders' equity | -7,669,000 | -7,615,000 | -7,832,000 | -8,152,000 | -8,727,000 |
| TOTAL | $47,901,000 | $38,827,000 | $36,905,000 | $36,024,000 | $33,003,000 |
| Total Liabilities And Equity | $81,414,000 | $73,214,000 | $74,438,000 | $75,196,000 | $72,548,000 |